Abbott

ABT

Market cap $225B

Abbott Laboratories (NYSE:ABT) stock fell around 2.6% on Wednesday after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Joanne Wuensch - Citigroup Inc., Research Division Travis Steed - BofA Securities, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good morning, and thank you for standing by.

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (ABT -3.20%) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the period ended September 30, 2025, filed on October 14, 2025.

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Abbott Laboratories (NYSE:ABT) reported steady growth in the third quarter, with sales rising 6.9% to $11.37 billion, slightly below estimates of $11.4 billion, and adjusted earnings per share matching expectations at $1.30. The company's results were driven by broad-based strength across Abbott's medical devices and diagnostics businesses, even as COVID-19 testing-related revenue continued to normalize.

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of short-term and often irrational market sentiment, limits fees and taxes, and (especially when dividends are reinvested) puts the magic of compounding to work.

Abbott (ABT) came out with quarterly earnings of $1.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.21 per share a year ago.

Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales.